Summary
Thermo Fisher Scientific Inc. (TMO) filed an 8-K on June 10, 2020, detailing significant amendments and new agreements related to its financing facilities. The primary focus is on the financing for its pending acquisition of QIAGEN N.V. The company entered into a Term Loan Credit Agreement for up to €3.0 billion, which replaces a portion of its existing bridge loan facility and is specifically intended to fund the QIAGEN acquisition. This new facility is a one-year senior unsecured term loan. In addition to the new term loan, TMO amended its existing Bridge Credit Agreement to increase the maximum leverage ratio to 5.0 to 1.0 and adjusted mandatory commitment reduction and prepayment provisions. Furthermore, the company amended and extended its $2.5 billion Revolving Credit Agreement, pushing the expiration date to July 1, 2022, and also increasing the maximum leverage ratio to 5.0 to 1.0 initially, with subsequent step-downs. These actions collectively demonstrate TMO's proactive management of its debt structure to support a major acquisition while maintaining financial flexibility.
Key Highlights
- 1Entered into a €3.0 billion senior unsecured one-year Term Loan Credit Agreement to fund the acquisition of QIAGEN N.V.
- 2Replaced €3.0 billion of the existing 364-day senior unsecured bridge loan facility with the new term loan.
- 3Amended the Bridge Credit Agreement to increase the maximum leverage ratio to 5.0 to 1.0 for the first two fiscal quarters post-drawing.
- 4Amended and extended the $2.5 billion Revolving Credit Agreement, extending its expiration to July 1, 2022.
- 5Increased the maximum leverage ratio in the Revolving Credit Agreement to 5.0 to 1.0 starting Q3 2020, with subsequent step-downs.
- 6The agreements signal Thermo Fisher's commitment to finalizing the QIAGEN acquisition and managing its financial obligations.
- 7The financing structure involves senior unsecured debt, reflecting the company's credit standing.